(Q51371803)

4 April 2018

title

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. (English)

1 reference

4 April 2018

main subject

bosutinib

1 reference

ChEBI release 2020-05-28

1 reference

Richat Abbas

1

1 reference

4 April 2018

Bruce A Hug

2

1 reference

4 April 2018

Cathie Leister

3

1 reference

4 April 2018

Myriam El Gaaloul

4

1 reference

4 April 2018

Stephan Chalon

5

1 reference

4 April 2018

Daryl Sonnichsen

6

1 reference

4 April 2018

publication date

21 June 2011

1 reference

4 April 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

4 April 2018

volume

69

1 reference

4 April 2018

issue

1

1 reference

4 April 2018

page(s)

221-227

1 reference

4 April 2018

https://scigraph.springernature.com/pub.10.1007/s00280-011-1688-7

exact match

0 references

cites work

Cellular functions regulated by Src family kinases

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1688-7

Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1688-7

Src activation regulates anoikis in human colon tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1688-7

The role of Src in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1688-7

The Src signaling pathway: a potential target in melanoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1688-7

The Abl family kinases: mechanisms of regulation and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1688-7

Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1688-7

Regulation of the c-Abl and Bcr-Abl tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1688-7

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1688-7

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1688-7

10.1007/S00280-011-1688-7

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

1 reference

4 April 2018